A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.

Vogelzang, N J; Aklilu, M; Stadler, W M; Dumas, M C; Mikulski, S M

Vogelzang, N J; Aklilu, M; Stadler, W M; Dumas, M C; Mikulski, S M.

Affiliation

Vogelzang NJ; Cancer Research Center, University of Chicago, IL 60637-1470, USA. nvogelza@medicine.bsd.uchicago.edu

Invest New Drugs ; 19(3): 255-60, 2001.

Article in En | MEDLINE | ID: mdl-11561684

Subject(s)

Antineoplastic Agents/therapeutic use; Carcinoma, Renal Cell/drug therapy; Kidney Neoplasms/drug therapy; Ribonucleases/therapeutic use; Adult; Aged; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/adverse effects; Carcinoma, Renal Cell/mortality; Carcinoma, Renal Cell/secondary; Female; Humans; Kidney Neoplasms/mortality; Kidney Neoplasms/pathology; Male; Middle Aged; Ribonucleases/administration & dosage; Ribonucleases/adverse effects; Survival Rate; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Ribonucleases / Carcinoma, Renal Cell / Kidney Neoplasms / Antineoplastic Agents Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2001 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links